Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Sep 30, 2025
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-09-26+78,250→ 78,250 totalExercise: $2.90Exp: 2035-09-25→ Common Stock (78,250 underlying) - Award
Performance Stock Units (PSUs)
2025-09-26+39,150→ 39,150 total→ Common Stock (39,150 underlying)
Footnotes (2)
- [F1]1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- [F2]Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.